Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI
Sponsor: Sun Yat-sen University